H.R. 10628 · 119th Congress · Health
Biosimilars Access and Affordability Act
- IntroducedSep 28, 2026 Done
- CommitteeReferred to 2 committees Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
No CRS summary yet; one usually follows within a few weeks of introduction.Who lobbies on it
4 organizations, more than 90% of House bills · 7 filings · Q3 2026These 4 organizations’ PACs gave $169K to 12 of the 12 members sponsoring or cosponsoring H.R. 10628 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
1 of 1 quarter
“H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and Affordability Act S. 5571: Biosimilars Access and Affordability Act Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Part D…”
$26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Merck & Co., Inc
1 of 1 quarter
“Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.”
$8.8M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Amgen Inc
1 of 1 quarter
“…HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act”
$8.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing
1 more organization, every filingPROUpgrade
Organizations that named H.R. 10628 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Sep 28, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sep 28, 2026Introduced in House